Development history

Discontinued & Abandoned Peptides

Peptide programmes can stop after efficacy or safety findings, commercial decisions, or long periods without documented progress. Stalled means quiet or paused — not confirmed discontinued — and every record keeps that distinction visible.

Three things people confuse when they say a peptide is 'available'

Current clinical development

An active trial programme under regulatory oversight. Not approved yet — but evidence is still being generated, and the scientific question is still open.

Regulatory availability

Approved medicines reach patients through licensed prescribers and pharmacies, for defined indications. Approval is indication-specific — never a general endorsement of every use being discussed online.

The unregulated market

A molecule can appear on research-chemical websites long after its development programme died — or without one ever existing. That kind of availability is a supply-chain fact, not an evidence signal. We never link to suppliers.

Discontinued does not mean dangerous

Development stops for many reasons: trials missing their endpoints, commercial decisions, better competitors, strategic pivots — and sometimes safety findings. "Discontinued" is a statement about a programme, not proof a molecule is poison. The reverse matters just as much: continued availability on the internet is not evidence of safety, efficacy or quality.

Online attention can outlive a programme

Some peptides remain heavily discussed after their original programme ended. Others have only gone quiet, with no formal discontinuation established. In both cases, online attention is a cultural signal — not evidence that development remains active, or that a peptide is safe or effective.

Browse the archive

Filter by documented lifecycle status, recorded stop reason and evidence level. Stalled records are included but never relabelled as discontinued.

Lifecycle status

Development status tells you what happened to the pharmaceutical programme, not whether a compound is safe or effective. Discontinued does not mean dangerous — most programmes stop for business reasons or because a trial did not show enough benefit. Where the reason is known, we state it.

Why development stopped

Evidence level

5 of 5 archived compounds

AOD-9604

Discontinued — efficacyL2Animal / lab studies

A growth-hormone fragment marketed for fat loss whose own obesity trials failed to establish a benefit.

Furthest established stage: Phase II

Stopped: Did not meet endpoints

Ipamorelin

Discontinued — efficacyL2Animal / lab studies

A selective growth hormone secretagogue discontinued after its trials missed their endpoints — now sold for physique and recovery claims no trial ever tested.

Furthest stage not established

Stopped: Did not meet endpoints

CJC-1295

DiscontinuedL3Early human studies

A long-acting GHRH analogue abandoned after early human studies — it reliably raises growth hormone, but the outcomes it is sold for were never tested.

Furthest established stage: Phase I

Stopped: Reason not established

ARA-290

StalledL3Early human studies

An 11-amino-acid EPO-derived peptide with real randomised human data in one narrow neuropathy setting.

Furthest established stage: Phase II

LL-37

StalledL3Early human studies

A human antimicrobial peptide studied topically for wound healing, now marketed for unrelated systemic uses.

Furthest established stage: Phase II

Stopped: Did not meet endpoints

Looking for compounds that did make it? Browse the full A–Z registry.